HomePipelinePNB-001Ulcerative Colitis

PNB-001

Ulcerative Colitis

PNB-001 for the Treatment of Ulcerative Colitis

Molecule
PNB-001
Development status
Phase 3 submission
Therapeutic area
Immune & inflammation
Biological action
CCK ligand, lymphokine, T-cell activation
Therapeutic target
Cholecystokinin/gastrin receptor ligand
Therapeutic indication
Ulcerative Colitis
Same study also covers
Crohn's Disease

Stage of development

  • PNB-001

    Ulcerative ColitisCCK ligand, lymphokine, T-cell activation

Graph of the stage of development of PNB-001 in Ulcerative Colitis. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

The study below is the company document “PNB-001 for the Treatment of Inflammatory Bowel Disease and Pain”, which covers Ulcerative Colitis and Crohn's Disease together.

Indication

Ulcerative Colitis

Indication

Crohn’s Disease

Background about target

The peptide cholecystokinin (CCK) was originally discovered in the gastrointestinal tract and has been shown to mediate pancreatic secretion and contraction of gallbladder. CCK was then described in the mammalian central nervous system (CNS) as a gastrin-like immunoreactive material. Two types of CCK receptors (type A, “alimentary”, and type B, “brain”) have been distinguished. CCK-A and CCK-B receptor types have been shown to differ by their relative affinity for the natural ligands, their differential distribution, and their molecular structure. Gastrin, a peptide hormone secreted by the parietal cells of the stomach, binds to CCK-B receptor and elicits its function. Upon binding to CCK2, it releases histamine, which in turn plays a role in releasing hydrochloric acid/gastric acid. In addition, gastrin also plays important roles in cell proliferation and maturation of the GI tract. Gastrin is also produced in excess in gastrinoma or gastric cancers. Inflammatory Bowel Syndrome patients (n=18) had higher secretion and sustained secretion of CCK after fat meal. CCK is also involved in GI motor response after meals. Hence, CCK receptor antagonists are recommended for IBD.

Preclinical studies:

PNB-001 is an isoform-selective antagonist that binds to CCK2 at 20 nM. In an isolated tissue assay, using CCK-5 as agonist the antagonizing properties were confirmed. At the same time PNB-001 was confirmed a CCK A agonists , a first in class CCK A agonist with CCKB antagonizing properties. L-365,260 was used as best CCK2 gastrin antagonist standard and PNB-001 was 10 times more potent and of much higher magnitude.

PNB-001 was tested in a rat model of indomethacin-induced IBD and was compared to positive control, prednisolone. PNB-001, at 5 mg/kg and 20 mg/kg p.o., was extremely effective in reducing the inflammation- and IBD-dependent damage to various gastrointestinal tissues and organs. Gross pathological changes and histopathological observations demonstrating IBD and Crohn’s Disease in this animal model were completely reversed by PNB-001. This reversal effect was dose dependent and highly consistent with CCK literatures.

In the hotplate model and the tail flick assay 0.5 mg/kg PNB001 is analog to 40 mg/kg tramadol was administered to mice and the latency period in a tail flick assay was measured. Subsequent experiments were performed to determine the dose and time response of PNB-001 analog to understand the longevity of the effect. In rats PNB-001 was administered orally and it demonstrated a sustained pain tolerance and these effects were either comparable or superior to the effect observed with tramadol.

Subsequently, we then evaluated the efficacy of PNB-001 analog in a more complex model of pain. Rats were grouped and a dose response curve of PNB-001 analog (P.O. or i.p.) was performed and compared to morphine in a formalin induced neuropathic (phase I) and inflammation pain (phase II) models. PNB-001 was extremely effective in this model of pain.

Preclinical development studies:

PNB-001 has a short half-life of 1.20 min in rat liver microsome and approximately 12 min in dogs and human liver microsome. Subsequent studies were performed to determine the pharmacokinetic (PK) properties of PNB-001. Rats were administered orally with 20 mg/kg PNB-001 to determine the circulating concentration. PNB-001 peak concentration was achieved at 40 min. PNB-001 had a half-life of 9 hrs and had a relatively low bioavailability. PNB-001 was evaluated in various ADME studies, including cytochrome P450 enzyme inhibition, plasma protein binding, and CaCo2 permeability. PNB-001 did not inhibit Cyp3A4, Cyp2C9, and Cyp1A2 up to 10 µM and Cyp2C19 until 3 µM. With 97% of PNB-001 bound to rat and human plasma, the amount of free unbound PNB-001 is comparable to some of the marketed drugs. CaCo2 permeability studies indicated that PNB-001 has high permeability and is not effluxed in the B>A direction.

Regulatory toxicology and safety pharmacology studies (acute toxicity studies in rats and mice, 7 day dose range finding studies in rats and dogs, 28 days toxicology studies in rats and dogs, PK studies in rats and dogs, safety pharmacology studies (cardiac, renal, respiratory, and neuro), chromosomal aberration and mutagenesis studies) conducted with PNB-001 under GLP environment and in accordance with ICH guidelines demonstrate extremely high levels of safety and tolerability.

Synthetic chemistry:

PNB-001 synthetic schema has been established both in non-GMP and in GMP conditions. Moreover, synthetic chemistry efforts are optimized to synthesize PNB-001 one a multi kg scale.

Formulation studies:

Formulation development, stability, and physicochemical characterization of PNB-001 were conducted. The studies demonstrated that PNB-001 was highly stable with ideal physicochemical properties. 50mg and 100mg hard gelatin capsules were prepared tested under GMP conditions.

Phase I clinical trials:

Phase I SAD clinical trial protocols had been completed and PNB-001 was found extremely safe over the dose range from 25-1500 mg. A MAD phase 1 clinical trial was also completed for 4 safety groups at low, medium and high doses (50, 100 and 200 mg) and in total PNB-001 is tested now in 74 healthy subjects. Overall PNB-001 was tested very safe and the target plasma concentrations were reached. AE were fond very mild, such as vomiting in a female subject and at a high dose, a 2.5 fold of ALT was identified.

Ongoing studies:

The indication inflammation with application in IBD is currently extended to COPD and Lung Cancer.

Phase 2 Ulcerative Colitis UC

PNB-001 was previously tested for Lung Inflammation in Covid-19 and was found safe and efficient. Now, PNB-001 was tested in phase 2 for gut inflammation in Ulcerative Colitis and Crohn’s Disease.

50 and 100 mg adjunct treatment was given to 29 UC and 12 CD patients receiving mesalamine for 28 days 3x daily. For UC stool frequency, rectal bleeding, mucosa appearance and physician assessment was analysed in form of the UCDAI. Mean with SD and response rates were analysed and presented.

In the mesalamine treatment group 4 of 9 (44%) subjects responded, compared to 5 of 9 (55%) to 50 mg and 8 of 9 (89%) to 100 mg adjunct treatment with PNB-001. The clinical effect is dose dependent and for mesalamine compared with 100 mg PNB-001 statistically significant with a P value P=0.05. This level of significance was observed for N=9 in only 28 days.

PNB-001 was found free from toxicity and efficient in UC and phase 3 clinical trials will follow in Q3 2024

Phase 2 : Crohn’s Disease CD

In addition to UC, Crohn’s Disease was tested in only a very small pilot trial with N=4 for mesalamine and 50 mg /100 mg adjunct treatment of PNB-001. The common CDAI (Crohn’s Disease activity index) was used for disease assessment. No disease reduction, compared to the mesalamine, was found in the adjunct treatment group.

Pain relief was seen in Crohn’s Disease patients and T cells showed the same trend in response to treatment.

Intellectual property

Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. USPTO has issued the patent on December 28, 2014. Composition of matter patent protection, so original patent protection, will expire in 2037. A further immune user patent will provide patent protection until 2042.

About PNB-001

Clinical · Phase 1 and Phase 2 completed

The front runner of the portfolio.
Developed from immune-mediated
Inflammatory research, PNB-001 is in Phase 3 for Covid-19 and has completed Phase 2 in Ulcerative Colitis & Crohn's Disease

PNB-001 full profile

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.